Acrivon Therapeutics, Inc. ACRV 深 沪
等待开盘 12-22 09:30:00 美东时间
2.16
-0.100
-4.42%
华盛通- 最 高2.28
- 今 开2.25
- 成交量 77.03万股
- 最 低 2.12
- 昨 收 2.26
- 总市值 6815.90万
- 52周最高 8.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.05
- 委 比 92.16%
- 总股本 3155.51万
- 历史最高 25.47
- 量 比 1.49
- 振 幅 7.08%
- 历史最低 1.05
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026
Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the
12-17 20:35
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.
11-25 19:45
Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses of $(0.59) per share
11-14 05:13
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
- Advancement ofRegistrational-intent Phase 2b trialofACR-368 andPhase1 trial ofACR-2316 in endometrial cancer andsolid tumor types. - Expansion ofGenerative Phosphoproteomics AP3 platform for target-centric drug discovery. - Financial update:Cash, cash equivalents, and marketable securities of$134.4 million as ofSeptember30, 2025. - Anticipated milestones:Reporting Phase2b trial update forACR-368 andPhase1clinical data forACR-2316 in2025.
11-13 21:10
Acrivon Therapeutics To Deliver Three Presentations At The AACR-NCI-EORTC Highlighting Advances From Its Proprietary Generative Phosphoproteomics AP3 Platform For Developing Precision Medicines
AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine developmentFavorable ACR-2316 preclinical data,
10-23 04:29
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
Acrivon Therapeutics announced three presentations at the AACR-NCI-EORTC conference showcasing their AP3 Generative AI platform and drug ACR-2316. The platform assesses drug effects on intracellular protein signaling networks for optimal drug design. ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated superior preclinical activity. Initial clinical data from its Phase 1 trial is expected later this year, with clinical activity already observed during...
10-22 20:15
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics granted equity awards in the form of stock options to an employee under its 2023 Inducement Plan. The options, totaling 225,000 shares, vest over four years with 25% after the first anniversary and monthly installments thereafter. Acrivon, a biotech company leveraging its proprietary Generative Phosphoproteomics AP3 platform, is advancing precision medicines, including ACR-368 in a Phase 2 trial for endometrial cancer and ACR...
10-01 20:30
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Shares of Robinhood Markets, Inc. (NASDAQ:HOOD) rose sharply in pre-market trad...
09-08 17:30
Acrivon Therapeutics Highlights Synergy in Updated Presentation
An update from Acrivon Therapeutics, Inc. ( ($ACRV) ) is now available. On Sept...
09-06 04:47
